Figure 6.

Anti-platelet drug ticagrelor, an antagonist of the purinergic receptor P2Y₁₂ receptor, reduces the effects of PR on cancer cells. Representative immunoblots show Slug, p-Akt and p-Erk expression in AsPC-1 and BxPC-3 cells after incubation with PR ± ticagrelor (Tica, 10 µM) for 2 h. Sample preparations and immunoblotting were performed as previously described. The final concentration of PR used was equivalent to releasate from 5 × 10⁸ platelets/mL. Bar graphs (C) and (D) show the expression levels of the proteins of interest relative to the loading control. Columns represent fold change in protein expression level compared to control non-treated cells. n ≥ 5. *** p < 0.0001, ** p < 0.001, ** p < 0.05. Data are presented as mean ± SEM. One way ANOVA with post-hoc Bonferroni’s Multiple Comparison Test was used to examine the significance of the mean. cont.: control.